

Amendments to the Claims:

1-18 (Canceled)

19. (Currently Amended) A method for preventing or reducing the risk of developing graft-versus-host disease in a recipient of an organ or tissue transplant, comprising:

administering to the transplant recipient ~~an adenosine deaminase inhibitor~~ pentostatin in a pharmaceutically effective amount within a predetermined time window ~~before or after~~ the transplantation.

20. (Canceled)

21. (Currently Amended) The method of claim 19, wherein ~~the adenosine deaminase inhibitor~~ pentostatin is administered orally to the transplant recipient.

22. (Currently Amended) The method of claim 19, wherein ~~the adenosine deaminase inhibitor~~ pentostatin is administered parenterally to the transplant recipient.

23. (Canceled)

24. (Canceled).

25. (Currently Amended) The method of claim ~~23~~ 19, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose between about 0.1-2 mg/m².

26. (Currently Amended) The method of claim ~~23~~ 19, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose between about 0.5-1 mg/m².

27. (Currently Amended) The method of claim ~~23~~ 19, wherein the transplant patient is transplanted with hematopoietic stem cells and treated in a myeloablative conditioning regimen.

28-30. (Canceled)

31. (Currently Amended) The method of claim ~~30~~ 19, wherein the transplant recipient is transplanted with hematopoietic stem cells.

32. (Currently Amended) The method of claim ~~31~~ 19, wherein pentostatin is administered to the transplant recipient at 0.5 – 1.5 mg/m²/day on days +8, +15, +22 and +30 following stem cell infusion.

33. (Original) The method of claim 19, further comprising: administering to transplant recipient an immunosuppressive agent selected from the group consisting of prednisone, methylprednisolone, cyclophosphamide, cyclosporin A, FK506, thalidomide, azathioprine, Daclizumab, Infliximab, MEDI-205, abx-cbl and ATG.

34-44 (Canceled)
